Accueil » Our platform » Midcap

Siparex Midcap
- A transformative shareholder for growth SMEs

Assets under management:

€600 M

Funds in the investment phase:

MIDCAP 3 – €170 M
Fonds France Nucléaire – €170 M

Position:

Majority or significant minority position

Company profiles:

Growth SMEs

All sectors of activity

Investment tickets:

from €5 M to €20 M

Project:

Capital development, Capital Transmission, Financing of external and organic growth

Investments.

Siparex Midcap accompanies growth SMEs in order
to transform them into ISEs that are champions in their sector.

Our Team.

The Siparex Midcap team systematically works closely with management teams, providing advice and solutions for company CEO as part of a trusting relationship.

Pierre BORDEAUX MONTRIEUX

Group Partner, Siparex Midcap, Member of the Executive Committee

Augustin de JERPHANION

Partner Siparex Midcap

Henri DUMAS

Partner Siparex Midcap

Yann RINCKENBERGER

Partner Siparex Midcap

Matthieu ADOIR

Senior Investment Manager Siparex Midcap

Stéphane AGAESSE

Senior Investment Manager Siparex Midcap

Etienne ARLET

Senior Investment Manager
Siparex Entrepreneurs, Siparex Midcap
(Toulouse)

Caroline MENGIN

Investment Manager Siparex Midcap

Pierre KOVALENKO

Investment Manager Siparex Midcap

Adrien ARMINJON

Senior Associate Siparex Midcap

Claire MOREL

Senior Associate Siparex Midcap

Tomaso BARBINI

Partner Insec

Andrea GIANOLA

Partner Insec

Jacopo ASINARI di BERNEZZO

Associate Insec

Fonds France Nucléaire

Subscribed equally by EDF and the French government and managed by Siparex, Fonds France Nucléaire invests in SMEs and ISEs in the nuclear sector, and accompanies them, in particular, in their organic and/or external growth projects as well as in their capital development, transmission, or share redistribution operations.

Find out more about Fonds France Nucléaire

Are you interested in investing
in the Midcap strategy?

The Investment and Development team is the key contact point for institutional and family office subscribers to our funds.

Meet the Investor Relations Team